Dyadic International Inc., DE

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dyadic International Inc. reports breakthrough year with promising C1 platform

Dyadic International Inc. delivered strong financial performance in FY 2022, marked by progress in trials, technology advancements, and strategic positioning in the biopharmaceutical sector. The company's focus on alternative proteins and cost-effective production methods aligns with industry trends and presents growth opportunities. Challenges lie in partnership execution, meeting analyst expectations, and navigating competitive pressures.

Dyadic International reports robust revenue growth and pursues vaccine innovation

Dyadic International's Q1 2023 performance reflects strong revenue growth, strategic collaborations, and a focus on innovation in vaccine production and healthcare solutions.
While facing challenges such as net losses and auditor transitions, the company is well-positioned to capitalize on opportunities in government grants, partnerships, and commercialization.

Dyadic International reports robust Q2 performance and advances in vaccine development

Dyadic International's Q2 2023 performance reflects strong revenue growth, successful Phase I trial progress, and improved financial metrics.
The company's strengths lie in their innovative C1 technology, strategic collaborations, and advancements in vaccine development for global health.
While facing challenges in cash burn and monetization, Dyadic has opportunities to expand collaborations, drive innovation, and address global health needs.
Overall, Dyadic is well-positioned to capitalize on its technological advancements, partnerships, and commitment to affordable healthcare solutions.

Dyadic International reports Q3 revenue challenges but optimistic growth outlook

Dyadic International's Q3 performance saw a decrease in research revenue but promising collaborations for future growth. The company's financials showed reduced operating expenses and a manageable net loss, with a healthy cash balance and sustainable cash burn rate. Strategic plans for revenue generation and confidence in future growth underscore Dyadic's resilience and potential in the market.

Dyadic International reports strong Q4 performance and growth opportunities

Dyadic International's Q4 2023 earnings call showcased positive performance, strong collaborations, and financial updates.
The company's focus on the C1 technology's potential in vaccines and proteins positions it for growth.
While challenges like equity components exist, Dyadic's strategic direction and leadership changes signal opportunities for expansion.

Dyadic International Inc. reports strong Q1 performance and growth opportunities

Dyadic International Inc. reported strong performance in revenue growth and product development in Q1 2024.
The company's strategic collaborations and financial stability position it well for future growth.
Challenges include leadership transitions, regulatory hurdles, and managing expenses.
Opportunities lie in industry interest, strategic partnerships, financial strength, and market expansion.

Dyadic International focuses on C1 technology for revenue growth

Dyadic International's Q2 2024 performance reflects a strategic focus on revenue growth through C1 technology and partnerships, despite a decrease in revenue and expenses.
The company's strengths in innovation, diversified market focus, and commitment to driving growth position it well for future opportunities and market expansion.
While facing challenges in revenue generation and market positioning, Dyadic International has opportunities to leverage its strengths in technology and partnerships for future growth and revenue optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The global distribution of Covid-19 vaccines has been dramatically short of hopes and expectations, but right in line with the warnings from skeptics who know the production constraints from traditional vaccines, which leverage established biotechnology for protein generation. However, there is a new platform driven by an upstart biotech company on the Nasdaq that may […]

A New Technology that Could Reshape the Vaccine Playing Field (NASDAQ: DYAI) (NASDAQ: AZN) (NASDAQ: MRNA) (NASDAQ: NVAX) (NYSE: PFE) (NYSE: JNJ) (NASDAQ: BNTX)

JUPITER, FL / ACCESSWIRE / April 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for quarter ended March 31, 2021 and host a corporate update conference call on Thursday, May 13, 2021. Conference Call Information Date: Thursday, May 13, 2021 Time: 5:00 p.m.

Dyadic to Report First Quarter 2021 Financial Results

India is burning in Covid flames. Brazil is in basically the same shape.

Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYAI)

Time for a New Vaccine Production Model? Spotlight on DYAI (NASDAQ: DYIA)

Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time Fireside Chat Being Held on Tuesday, May 4th @ 10am Eastern Time

Dyadic International Hosting a Fireside Chat on “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”

Bloomberg reported this morning that the world's wealthiest countries are vaccinating 25 times faster than the poorest. As of April 8, 40% of the shots administered have gone to people in 27 nations that represent just 11% of the global population.

Is Dyadic International Inc. (NASDAQ: DYAI) the Key to the Next Wave of Vaccinations? (NASDAQ: AZN) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: NVAX)

Death, Taxes, and Covid shots. The future stretching out in front of us has maybe only these three certainties.

How Dyadic International Inc (NASDAQ: DYAI) Fits into the Vaccine 2.0 Gold Rush (NASDAQ: BNTX) (NYSE: JNJ) (NASDAQ: MRNA) (NYSE: PFE)

Dyadic International Inc's (DYAI) CEO Mark Emalfarb on Q4 2020 Results - Earnings Call Transcript

Advancing Dyadic ' s proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercialization To serve as proof of concept for next-generation multivalent COVID-19 vaccine candidates Expanded Korea and Southeast Asia vaccine development partnership with Medytox (086900) (KOSDAQ) focused on next-generation COVID-19 variant vaccines and/or boosters In parallel with DYAI-100, additional proprietary and third-party COVID-19 variant vaccine candidates are under development Developing a number of other infectious disease vaccines and antibodies internally and in conjunction with others Expanding commercial opportunities of C1 technology through eleven new and two expanded collaborations for human and animal health applications C1 selected by ZAPI (Zoonosis Anticipation Preparedness Initiative) as a vaccine manufacturing platform for more efficient production of antigens that are safe, effective, and protective Cash and investment grade securities of $29.2 million at year-end 2020 JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs and other commercial products at flexible commercial scales, today announced its financial results for 2020 and recent business highlights. "We are very pleased with substantial progress made thus far in 2021 and over the course of 2020.

Dyadic Reports 2020 Year End Results and Recent Company Progress

While the pandemic feels “almost over” on many levels, experts believe the fundamental driver – a rapidly mutating coronavirus pathogen with uniquely formidable qualities – is likely, and unfortunately, here to stay as an endemic feature of the human microbiome going forward. In other words, Covid-19 is going to be with us for the long […]

Is Dyadic International Inc (NASDAQ: DYAI) the Key to Scaling Up Global Access to a Viable Covid-19 Vaccine? (NASDAQ: NVAX) (NASDAQ: MRNA) (NYSE: PFE) (NASDAQ: AZN)

JUPITER, Fla., March 29, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today is updating the market on the progress made in certain of its coronavirus (COVID-19) and other infectious disease programs.

UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial

JUPITER, Fla., March 23, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the Company is expanding its partnership with South Korea's Medytox, Inc. (“Medytox”), a global biopharmaceutical company with sales in approximately 60 countries. Dyadic and Medytox will co-develop C1 manufactured COVID-19 vaccines and/or boosters, which will, if successful, be used to immunize people against two or more of the current and future COVID-19 variants. This project can provide dedicated local supply, to help combat COVID-19, in this region of the world.

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

Dyadic International is surging today after it announced a Covid vaccine partnership with Medytox, but that isn't the only bullish news for this small cap biotech stock. The post DYAI Stock: Why Covid-19 Vaccine Play Dyadic Is Shooting Higher Today appeared first on InvestorPlace.

DYAI Stock: Why Covid-19 Vaccine Play Dyadic Is Shooting Higher Today

Marker Therapeutics Inc

Odonate Therapeutics

Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut Shop: Odonate, an oncology-focused pharma company, said it is discontinuing the development of tesetaxel following feedback from the Food and Drug Administration in a pre-New Drug Application meeting.

Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday

The stock price of Dyadic International, Inc. (NASDAQ: DYAI) increased by over 30% pre-market. This is why it happened.

DYAI Stock Price Increases Over 30% Pre-Market: Why It Happened

Dyadic International Inc's (NASDAQ: DYAI) initial C1 produced SARS-CoV-2-S-RBD vaccine candidate, DYAI-100, moves towards the first human Phase 1 clinical trial to assess the safety and preliminary efficacy of the vaccine. The company has entered into a master services agreement with CR2O, a contract research organization, to manage the preclinical and clinical development of DYAI-100.

Dyadic's COVID-19 Vaccine Candidate Comes One Step Closer To Enter Human Trials

JUPITER, FL / ACCESSWIRE / March 16, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its financial results for full year ended December 31, 2020 and host a corporate update conference call on Tuesday, March 30, 2021. Conference Call Information Date: Tuesday, March 30, 2021 Time: 5:00 p.m.

Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results

Results demonstrate that Dyadic's C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trials Results demonstrate that Dyadic's C1 platform produced record levels of safe and effective vaccines in animal trials and further positions C1 products for potential human clinical trials

Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting

JUPITER, FL / ACCESSWIRE / January 11, 2021 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs, and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced the appointment of Patrick Lucy, to its Board of Directors, effective January 8, 2021. Mr. Lucy will serve as an independent director and a member of the Board's Science and Technology Committee.

Dyadic International Appoints New Board Member

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2020 Results - Earnings Call Transcript

This small-cap stock is developing a technology that could revolutionize biotech.

This Revolutionary Biotech Is Shrouded in Mystery. Is It a Buy?

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q1 2020 Results - Earnings Call Transcript

Dyadic International: The Pandemic Changes Everything

Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q4 2019 Results - Earnings Call Transcript

Dyadic International, Inc. (NASDAQ: DYAI) shares are trading higher on Thursday, after the company announced its platform is to be used by the Israeli Research Institution to develop a treatment for the COVID-19.

News for Dyadic International Inc., DE Stock (DYAI)